Topical application of the TLR7 agonist imiquimod (IMQ) to the skin leads to psoriatic skin inflammation in mice, which is associated with many hallmarks of human psoriasis, including increased epidermal proliferation, hyperkeratosis, scaling, and erythema16. Here, TLR7 is linked to psoriasis.